Loading…
GT Biopharma, Inc.
How the company evolved, year by year. Revenue and debt come from the annual reports — for most companies, the 10-K filings with the SEC since 2009; dividends from the payments themselves.
The bars are a balance on the closing date; the lines are what happened during the year. Revenue above equity is ordinary, not an anomaly — it means the company turns its capital over more than once a year.
Major managers that reported this stock in their latest 13F.
None of the investors we track reported a position in GTBP.
▼ -96.4% over 5Y.
today you would have $34.08▼ -96.6%
Dividends reinvested, splits accounted for. Past prices say what happened, not what will.
The last 4 closed years. Each multiple uses that year’s closing price and that year’s reported numbers — not today’s. The range is set by the annual reports on record.
| Indicator | Median | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Year-end price | $19.63 | $3.05 | $7.65 | $26.58 | |
| P/B | 2.5x | 86.6x | — | 1.4x | 2.5x |
| EPS | -$6.68 | -$6.94 | -$5.64 | -$19.46 | |
| ROE | -177.98% | -489.96% | — | -101.62% | -177.98% |
Median, not average: a single year of near-zero profit produces a P/E of 400 and would drag an average on its own. P/E years above 200x are left out, the same cut the fair price uses — so this median matches the “its own history” method below. Price and EPS have no median: they are series that grow.
Companies of similar size in Healthcare, for comparison. The columns are the same ones above, in the same order.
| Stock | Price | P/E | P/B | Dividend yield | ROE | Market cap |
|---|---|---|---|---|---|---|
| ICUSeaStar Medical Holding Corp | $3.09 | — | 3.1x | — | -356.87% | $13.62M |
| HSCSHeartSciences Inc. | $3.03 | — | 42.7x | — | -4239.91% | $13.65M |
| KALAKALA BIO, Inc. | $0.69 | — | 1.5x | — | -345.32% | $13.35M |
| INTSIntensity Therapeutics Inc | $4.25 |
GT Biopharma, Inc., a clinical stage biopharmaceutical company, engages in the development and commercialization of immuno-oncology products based on its Tri-specific Killer Engager (TriKE) and Tetra-specific Killer Engager (Dual Targeting TriKE) platforms. It develops GTB-3650, which is in phase 1 trials that target CD33 on the surface of myeloid leukemias and an agonistic camelid; GTB-5550, that is in phase 1 dose escalation basket trial that targets B7-H3 on the surface of advanced solid tumors;and GTB-7550, a pre-clinical stage product candidate in development for the treatment of lupus and other autoimmune disorders. The company was formerly known as OXIS International, Inc. and changed its name to GT Biopharma, Inc. in July 2017. GT Biopharma, Inc. was incorporated in 1965 and is based in San Francisco, California.
Company description provided by Yahoo Finance.
| — |
| 1.4x |
| — |
| -195.88% |
| $13.88M |
| PHIOPhio Pharmaceuticals Corp. | $1.13 | — | 1.0x | — | -113.71% | $13.13M |
| RGNTRegentis Biomaterials Ltd | $2.00 | — | 2.2x | — | — | $14.05M |